These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27166270)

  • 1. Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
    de Miguel-Luken MJ; Chaves-Conde M; Quintana B; Menoyo A; Tirado I; de Miguel-Luken V; Pachón J; Chinchón D; Suarez V; Carnero A
    Oncotarget; 2016 May; 7(22):31723-37. PubMed ID: 27166270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.
    de Miguel-Luken MJ; Chaves-Conde M; de Miguel-Luken V; Muñoz-Galván S; López-Guerra JL; Mateos JC; Pachón J; Chinchón D; Suarez V; Carnero A
    Oncotarget; 2015 May; 6(14):12625-36. PubMed ID: 25788275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx.
    Chen AM; Hsu S; Meshman J; Chin R; Beron P; Abemayor E; St John M
    Head Neck; 2017 Jul; 39(7):1322-1326. PubMed ID: 28301066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
    Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
    Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
    Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
    Bar-Ad V; Wang ZX; Leiby B; Tuluc M
    J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.
    Fuller CD; Mohamed AS; Garden AS; Gunn GB; Mulcahy CF; Zafereo M; Phan J; Lai SY; Lewin JS; Hutcheson KA; Frank SJ; Beadle BM; Morrison WH; El-Naggar AK; Kocak-Uzel E; Ginsberg LE; Kies MS; Weber RS; Rosenthal DI
    Head Neck; 2016 Dec; 38(12):1739-1751. PubMed ID: 27466789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma.
    Wang H; Zhang Z; Sun R; Lin H; Gong L; Fang M; Hu WH
    J Voice; 2015 May; 29(3):356-62. PubMed ID: 25484261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
    Ahn D; Sohn JH; Kim JH; Lee JE; Park SH; Kim JC
    Ear Nose Throat J; 2016 Feb; 95(2):E34-42. PubMed ID: 26930342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.
    Birkeland AC; Beesley L; Bellile E; Rosko AJ; Hoesli R; Chinn SB; Shuman AG; Prince ME; Wolf GT; Bradford CR; Brenner JC; Spector ME
    Head Neck; 2017 Dec; 39(12):2512-2518. PubMed ID: 28963806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
    Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear survivin expression correlates with endoglin-assessed microvascularisation in laryngeal carcinoma.
    Marioni G; Ottaviano G; Marchese-Ragona R; Fasanaro E; Tealdo G; Zanotti C; Randon B; Giacomelli L; Stellini E; Blandamura S
    J Clin Pathol; 2017 Dec; 70(12):1033-1037. PubMed ID: 28446541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.